Port Hueneme-based Stellar Biotechnologies acquired a privately held Canadian therapeutics firm Edesa as a subsidiary in a share exchange March 8 and said it may decide to wind down its legacy manufacturing operations. Stellar issued new common stock in exchange for Edesa shares, leaving Edesa shareholders with a 90 percent interest in Stellar and current…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
